

**I. June 2025 Revenue: Summary by Channel**

1. NT\$ Reporting for 4137 TT	June 2025 (NT\$m)	% MoM	% YoY
Consolidated Sales	285.0	-15%	-6%
Channel – Beauty Salon Franchise (mainland China)	247.8	-18%	-7%
Channel – Beauty Salon Franchise (Taiwan, Vietnam, etc.)	11.4	-16%	-20%
Channel – Internet Retailing	14.6	80%	52%
Channel – Medical Beauty Clinics	11.2	22%	-5%
NT\$/RMB avg. exchange rate (June)	4.1215	----	----
2. RMB Reporting for 4137 TT	June 2025 (RMBm)	% MoM	% YoY
Consolidated Sales	69.1	-12%	2%
Channel – Beauty Salon Franchise (mainland China)	60.2	-16%	0%
Channel – Beauty Salon Franchise (Taiwan, Vietnam, etc.)	2.8	-13%	-13%
Channel – Internet Retailing	3.4	79%	59%
Channel – Medical Beauty Clinics	2.7	22%	3%
3. TWD Reporting	Jan. to June 2025 (NT\$m)	% MoM	% YoY
Consolidated Sales	1,750.6	----	-13%
Channel – Beauty Salon Franchise (mainland China)	1,552.7	----	-13%
Channel – Beauty Salon Franchise (Taiwan, Vietnam, etc.)	74.8	----	-15%
Channel – Internet Retailing	49.4	----	-6%
Channel – Medical Beauty Clinics	73.7	----	-18%
NT\$/RMB average exchange rate	4.3824	----	----
4. RMB Reporting	Jan. to June 2025 (RMBm)	% MoM	% YoY
Consolidated Sales	399.5	----	-13%
Channel – Beauty Salon Franchise (mainland China)	354.3	----	-12%
Channel – Beauty Salon Franchise (Taiwan, Vietnam, etc.)	17.1	----	-14%
Channel – Internet Retailing	11.3	----	-5%
Channel – Medical Beauty Clinics	16.8	----	-17%



5. Franchise Store Count	End of June 2025	Net Change in June	YTD Net Change	YoY %
Total	4,445	-66	-142	-8%
China	4,201	-66	-141	-8%
Taiwan	225	0	-1	0%
Southeast Asia	19	0	0	0%

II. Major Upcoming Events and Press Release

1. **Financial Briefing:** None.
2. **Major Meetings:** None.
3. **Other Topics:** None
4. **Press Release:**

CHLITINA HOLDING LIMITED announced a consolidated revenue for June 2025 of RMB 69 million, a 2% increase compared to the same period last year. The second-quarter revenue was RMB 223 million, a 26% increase quarter-over-quarter. The fiscal subsidy income of RMB 18 million for 2025 has been recorded.

Taipei, July 8, 2025

CHLITINA HOLDING LIMITED (stock code: 4137, hereafter referred to as Chlitina) announced today (July 8) that the consolidated revenue for June 2025 was RMB69 million, a 2% increase compared to the same period last year. The consolidated revenue for the second quarter was RMB223 million, a 26% increase compared to the first quarter.

Chlitina stated that the main reason for the revenue growth in the second quarter compared to the first quarter was the increased shipments of various new functional products, coupled with the rising demand for summer skin care, which drove the growth of both online and offline channels, leading to a 26% increase in quarterly revenue. Furthermore, in response to the rapid transformation of the consumer market towards medical aesthetics, personalization, and health orientation, Chlitina has been actively promoting the core concept of medical-grade skincare in recent years. By deepening product development and advancing digital upgrades as dual growth drivers, we continue to enhance the value of member engagement. Through optimizing the membership tier system, implementing precise push notification mechanisms, and designing personalized experiences, we effectively boost member participation and conversion efficiency. At the same time, Chlitina is actively expanding e-commerce and social new retail channels to deepen a sales strategy that operates across all time periods and without geographic limitations.

Looking ahead to the third quarter of 2025, Chlitina maintains a cautiously optimistic outlook. Its new flagship medical-grade skincare line, the “Skin Radiance Refining Series,” is the world’s first high-performance anti-aging product to feature active ingredients extracted from deer amniotic liquid and PDRN. With the arrival of the peak summer season for whitening products, several star functional items—such as the “White Crystal Dark Spot Correcting Series” and the “SPF50 PA++ Whitening

IR contact:
Laurence Marcout

Tel:
(+886-2) 8758-0370

E-mail:
ir@chlitinaholding.com



Sunscreen” both with national-level whitening and spot-reducing certifications—are entering a strong sales cycle. These products are expected to further elevate brand strength in the mid-to-high-end consumer market, not only increasing overall average transaction value and customer loyalty for Chlitina, but also driving steady growth momentum for the group. The company remains highly confident in achieving year-over-year monthly and quarterly revenue growth in the second half of the year.

About CHLITINA

- ◆ **Main Business:** Beauty and personal care products. Channels: Beauty salon franchise; Self-operated medical beauty clinics; Self-operated e-commerce platform.
- ◆ **Current Market Positioning:** Mid-to-high-end beauty salon franchise business – Industry leader in the franchise business, while also developing related ancillary channels and products.
- ◆ **Primary Market Focus:** Chinese-speaking regions in Asia.
- ◆ **Business Model:** The Company develops, manufactures, markets and sells its own brand of beauty and personal care products through franchised beauty salons. In recent years, we have been working on business diversification through new strategies including creating the UPLIDER medical beauty clinics and the JINGHE and HEDENG general clinics, developing the CHLITINA HOME SPA omnichannel retail and investing in RnD Nail & Eyelash stores among other subsidiary channels.
- ◆ **Brand Background:** CHLITINA was founded in Taiwan in 1989 by Dr. Chen Wu-kang who successfully developed skin care products based on amino acids. In 1997, Chairman Joanna Chen brought the CHLITINA brand to the Chinese mainland market where its high-quality products and effective business model have been keys to its remarkable success.
- ◆ **New Developments:** In addition to operating a large beauty salon franchise, in recent years, CHLITINA has been collaborating with academic and medical circles on R&D projects regarding stem cells, as well as anti-ageing and regenerative medicine. We have also made strategic investments in the biotechnology industry. In the long term, we are confident that this strategy will inject new blood into the group.